Eric Frings joins Intercell Biomedical Ltd. as Site Director

Eric Frings joins Intercell Biomedical Ltd. as Site Director


Vienna (Austria), October 4, 2010 - Intercell AG (VSE: ICLL) today announced that Eric Frings has joined the Company as new Site Director of Intercell Biomedical Ltd. in Livingston, Scotland. He gained expertise in the vaccine business from positions in Global Operations with Chiron Vaccines and lately Novartis Vaccines, Marburg, Germany, where he held a number of wide ranging positions of increasing responsibility.

 

Eric Frings has a proven track record in overseeing viral and bacterial vaccines manufacturing operations within a highly regulated quality compliance setting.

Intercell Biomedical Ltd. is dedicated to the production of IXIARO®/JESPECT®, Intercell's vaccine against Japanese Encephalitis, which is licensed in the U.S., Europe, Australia, and Canada.

About Intercell AG

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.

The Company's technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth).

The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: www.intercell.com

Please note that a photo of Eric Frings is available upon request.


Contact Intercell AGIntercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Campus Vienna Biocenter 3, A-1030 Vienna
P: +43-1-20620-1303
Mail to: [email protected]

 

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

Hollie Vile
Consultant
Capital MSL
81 Whitfield Street
London W1T 4HG
t. +44 (0) 20 7307 5340 f. +44 (0) 20 7307 5331

e: [email protected]
w: http://www.capitalmsl.com

 

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.